Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reset for menopause treatment.

Annals of internal medicine·2026
Same author

Physicians chart new path into direct primary care.

Medical economics·2016
Same author

Surviving the transition from independent to employed.

Medical economics·2016
Same author

Cooperate, don't compete, with retail clinics.

Medical economics·2016
Same author

UK Groups Plan Cancer Research Hub.

Cancer discovery·2016
Same author

NCI-MATCH Trial Draws Strong Interest.

Cancer discovery·2016

Related Experiment Video

Updated: Mar 31, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K

Is PD-L1 Expression a Biomarker of Response?

Janet Colwell

    Cancer Discovery
    |October 31, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Programmed cell death-1 (PD-1) receptor drugs show antitumor promise. However, PD-L1 ligand expression is not a definitive biomarker for treatment response, as other factors also influence outcomes.

    More Related Videos

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.3K
    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.2K

    Related Experiment Videos

    Last Updated: Mar 31, 2026

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K
    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.3K
    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.2K

    Area of Science:

    • Oncology
    • Immunotherapy
    • Molecular Biology

    Background:

    • Investigating the efficacy of drugs targeting the programmed cell death-1 (PD-1) receptor in cancer treatment.
    • Evaluating the role of the programmed cell death-1 ligand (PD-L1) as a predictive biomarker for response to PD-1 blockade therapy.

    Discussion:

    • The expression of PD-L1 is increasingly recognized as one among multiple variables influencing patient response to PD-1 inhibitors.
    • Current research suggests that a complex interplay of factors, beyond PD-L1 status, determines the effectiveness of PD-1 blockade immunotherapy.

    Key Insights:

    • PD-1 targeted therapies demonstrate significant antitumor activity in clinical settings.
    • PD-L1 expression alone is insufficient to reliably predict response to PD-1 blockade.
    • Multiple biological and clinical variables modulate the efficacy of PD-1 pathway inhibitors.

    Outlook:

    • Further research is needed to identify and validate additional biomarkers for PD-1 blockade therapy.
    • Developing comprehensive predictive models incorporating diverse factors will enhance patient selection for immunotherapy.
    • Optimizing combination strategies may overcome resistance mechanisms and improve outcomes in PD-1 targeted cancer treatment.